Core Viewpoint - The company plans to issue shares to acquire 100% equity of Weigao Puri from Weigao Co., Weihai Shengxi, and Weihai Ruiming, which is expected to constitute a major asset restructuring for the listed company [2] Group 1: Transaction Details - The transaction will add new business lines in the research, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems [2] - Following the completion of the transaction, the company aims to integrate the target company's technological accumulation and product layout to expand its product line into the pharmaceutical packaging sector [2] Group 2: Strategic Benefits - The company plans to leverage its own hollow fiber filtration technology advantages alongside the target company's rich customer resources in the biopharmaceutical sector [2] - This collaboration is expected to enable mutual empowerment in product technology reserves and sales channels for biopharmaceutical filter business, focusing on the upstream market of biopharmaceuticals [2]
威高血净开盘涨停，公司拟发行股份购买威高普瑞100%股权